Volinanserin is primarily investigated for its potential therapeutic applications in the field of psychiatry and neurology. It functions as a selective 5-HT2A receptor antagonist, which makes it a candidate for treating conditions related to serotonin dysregulation. One of its key applications is in the management of psychiatric disorders such as schizophrenia, where it may help alleviate symptoms like hallucinations and delusions by modulating serotonin activity. Additionally, it has been studied for its potential use in addressing sleep disturbances, particularly insomnia, due to its ability to influence serotonin pathways involved in sleep regulation. Research has also explored its role in reducing the negative effects of psychedelic substances by blocking the 5-HT2A receptor, which is crucial for their hallucinogenic effects. Overall, Volinanserin holds promise in improving mental health and sleep-related conditions through its targeted action on serotonin receptors.